Table 1.
Patient demographics and cohort data for phase II anti-VEGF trials in recurrent GBM.
| Trial | Number of Patients | Age | Tumor Volume [cc] | ADCL [um2/ms] | Median OS [Months] | |
|---|---|---|---|---|---|---|
| Training | Cediranib (NCT00035656) | 30 | 51.8 ± 2.4 | 35.6 ± 6.1 | 1.29 ± 0.04 | 7.6 |
| Bevacizumab (NCT00345163) | 57 | 51.8 ± 1.5 | 19.4 ± 2.2 | 1.18 ± 0.03 | 10.7 | |
| Cabozantinib (NCT00704288) | 65 | 52.5 ± 1.5 | 27.5 ± 3.4 | 1.16 ± 0.03 | 8.4 | |
| Aflibercept (NCT00369590) | 25 | 54.0 ± 2.2 | 17.9 ± 3.7 | 1.18 ± 0.05 | 9.9 | |
|
| ||||||
| Total (Pooled) Anti-VEGF Tx Naïve | 177 | 52.4 ± 0.9 | 24.9 ± 1.9 | 1.19 ± 0.02 | 9.3 | |
| Training Cohort | ||||||
|
| ||||||
| Validation | BELOB (Monotherapy Arms) | 81 | 65.2 ± 1.0 | 17.7 ± 1.8 | 1.21 ± 0.03 | 8.3 |
| Bevacizumab Monotherapy | 42 | 56.3 ± 1.5 | 19.6 ± 2.4 | 1.20 ± 0.03 | 8.4 | |
| Lomustine Monotherapy | 39 | 56.0 ± 1.4 | 15.7 ± 2.6 | 1.22 ± 0.04 | 8.2 | |